Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.28306PMID 23922205
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2013

  2013cited by this paper
• Clinical responses to selumetinib (AZD6244; ARRY‐142886)‐based combination therapy stratified by gene mutations in patients with metastatic melanoma

  2013cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• New strategies in melanoma: molecular testing in advanced disease.

  2012cited by this paper
• Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

  2012cited by this paper
• NRAS mutation status is an independent prognostic factor in metastatic melanoma

  2012cited by this paper
• Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

  2012cited by this paper
• Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

  2012cited by this paper
• Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

  2012influential reference
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• A landscape of driver mutations in melanoma.

  2012cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• Melanoma genome sequencing reveals frequent PREX2 mutations

  2012cited by this paper
• Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

  2012influential reference
• Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

  2011cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants

  2007cited by this paper
• NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing

  2006cited by this paper
• Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

  2006cited by this paper
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Cancer statistics

  1989cited by this paper

• Conjunctival melanoma genomic analysis reveals intermediate tumor mutation burden and genomic overlap with cutaneous melanoma

  2025cites this paper
• Current and emerging treatment options for BRAFV600-mutant melanoma

  2025cites this paper
• Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics

  2024cites this paper
• Sex Differences in Odds of Brain Metastasis and Outcomes by Brain Metastasis Status after Advanced Melanoma Diagnosis

  2024cites this paper
• Prognostic and predictive biomarkers in melanoma.

  2023cites this paper
• Clinicopathologic and genetic characterization of invasive melanoma with BRAF V600K mutation: A study of 16 cases

  2023cites this paper
• Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).

  2023cites this paper
• Activation mechanisms of clinically distinct B‐Raf V600E and V600K mutants

  2022cites this paper
• Liquid biopsies to occult brain metastasis

  2022cites this paper
• Low-metastatic melanoma cells acquire enhanced metastatic capability via exosomal transfer of miR-199a-1-5p from highly metastatic melanoma cells

  2022cites this paper
• Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.

  2022cites this paper
• Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma

  2022cites this paper
• The frequency and clinicopathological significance of NRAS mutations in primary cutaneous nodular melanoma in Indonesia

  2021cites this paper
• Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma

  2021cites this paper
• Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain☆☆☆

  2020cites this paper
• Management of brain metastases according to molecular subtypes

  2020cites this paper
• Patients with metastatic melanoma receiving anticancer drugs: changes in overall survival, 2010-2017.

  2020cites this paper
• [he role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma].

  2020cites this paper
• Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019.

  2020cites this paper
• Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients

  2019cites this paper
• Mutacije gena BRAF i NRAS u pacijenata s melanomom kože čiji su tkivni uzorci analizirani tijekom 2017. i 2018. godine u Kliničkom bolničkom centru Split

  2019cites this paper
• Dedifferentiated Melanoma With Expression of Cytokeratin and GATA3 in a Patient With History of Breast Carcinoma.

  2019cites this paper
• Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

  2019cites this paper
• Adjuvant therapy for cutaneous melanoma: a systematic review and network meta‐analysis of new therapies

  2019cites this paper
• Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

  2019cites this paper
• Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.

  2019cites this paper
• Melanoma brain metastases harboring BRAFV600K or NRAS mutations are associated with an increased local failure rate following conventional therapy

  2018cites this paper
• Pharmacokinetic Evaluation of [11C]CEP-32496 in Nude Mice Bearing BRAFV600E Mutation-Induced Melanomas

  2018cites this paper
• Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma

  2018cites this paper
• Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma

  2017cites this paper
• Correlation of histopathologic characteristics to protein expression and function in malignant melanoma

  2017cites this paper
• Management of intracranial melanomas in the era of precision medicine.

  2017cites this paper
• MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line

  2017cites this paper
• Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers.

  2017cites this paper
• Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.

  2017influential citation
• Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

  2017influential citation
• Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Endometrium.

  2017cites this paper
• Tumour mutation status and sites of metastasis in patients with cutaneous melanoma

  2017cites this paper
• Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

  2017cites this paper
• Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date

  2017cites this paper
• Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma

  2017cites this paper
• BRAF‐V600 mutational status affects recurrence patterns of melanoma brain metastasis

  2017cites this paper
• Management of intracranial melanomas in the era of precision medicine

  2017cites this paper
• Liquid Biopsies in Malignant Melanoma: From Bench to Bedside

  2017cites this paper
• A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors

  2016cites this paper
• Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

  2016cites this paper
• BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study

  2016cites this paper
• Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.

  2016cites this paper
• NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand

  2016cites this paper
• BRAF and Epithelial-Mesenchymal Transition: Lessons From Papillary Thyroid Carcinoma and Primary Cutaneous Melanoma

  2016cites this paper
• BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival

  2016cites this paper
• Principles of Melanoma Staging.

  2016cites this paper
• Metastatic melanoma treatment: Combining old and new therapies.

  2016cites this paper
• Dissection of the Process of Brain Metastasis Reveals Targets and Mechanisms for Molecular-based Intervention.

  2016cites this paper
• Mechanisms of Oncogene Activation

  2016influential citation
• Germline determinants of clinical outcome of cutaneous melanoma

  2016cites this paper
• Patient-derived tumor xenograft models for melanoma drug discovery

  2016cites this paper
• Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma.

  2016cites this paper
• Biology and treatment of BRAF mutant metastatic melanoma.

  2016cites this paper
• results from a randomised, double-blind, phase 3 trial

  2016cites this paper
• Unravelling molecular mechanisms underlying therapy resistance in cutaneous melanoma

  2016cites this paper
• Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries

  2015cites this paper
• Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.

  2015cites this paper
• Endoscopic ultrasound fine-needle aspiration cytology mutation profiling using targeted next-generation sequencing: personalized care for rectal cancer.

  2015cites this paper
• Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets

  2015cites this paper
• Isothiouronium salts reduce NRAS expression, induce apoptosis and decrease invasion of melanoma cells.

  2015cites this paper
• Investigating the effects of Wnt/β-catenin Signalling on Melanoma Cell Metabolism and Mitochondrial Dynamics

  2015influential citation
• Converting biology into clinical benefit: lessons learned from BRAF inhibitors.

  2015cites this paper
• Estudi de les alteracions genètiques en melanoma cutani mitjançant hibridació in situ fluorescent: valor diagnòstic i pronòstic

  2015cites this paper
• E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.

  2015cites this paper
• NRASQ61R, BRAFV600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

  2015cites this paper
• The Cancer Genomics Resource List 2014.

  2015cites this paper
• Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients

  2015cites this paper
• BRAF in early stage melanoma: rationale for testing and treatment?

  2015cites this paper
• Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

  2015cites this paper
• Melanoma: Advances in Targeted Therapy and Molecular Markers

  2015cites this paper
• Lymph node metastases of melanoma: challenges for BRAF mutation detection.

  2015cites this paper
• Systemic therapies for melanoma brain metastases: which drug for whom and when?

  2015cites this paper
• BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma

  2015cites this paper
• The genetic basis of new treatment modalities in melanoma.

  2015cites this paper
• The role of BRAF mutations in primary melanoma growth rate and survival

  2015cites this paper
• Nras in melanoma: targeting the undruggable target.

  2014cites this paper
• Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations

  2014cites this paper
• Oncogenes in melanoma: an update.

  2014cites this paper
• Universes collide: combining immunotherapy with targeted therapy for cancer.

  2014cites this paper
• Genotyping of cutaneous melanoma.

  2014cites this paper
• Dabrafenib for the treatment of melanoma

  2014cites this paper
• Biology of Human Tumors Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB / C Melanoma Patients with BRAF V 600 Mutations

  2014cites this paper
• Participation of the elderly population in clinical trials: barriers and solutions.

  2014cites this paper
• Section IV: non-small cell lung cancer and malignant melanoma.

  2014cites this paper
• Emerging insights into resistance to BRAF inhibitors in melanoma.

  2014cites this paper
• Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma

  2014cites this paper
• Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma

  2014cites this paper
• Targeted therapy in melanoma: the era of personalized medicine

  2014cites this paper
• Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma

  2014cites this paper
• Prognostic Value Analysis of Mutational and Clinicopathological Factors in Non-Small Cell Lung Cancer

  2014cites this paper
• Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

  2014influential citation
• AVALIAÇÃO IN VITRO DOS EFEITOS CITOTÓXICOS E ANTIMETASTÁTICOS DE SAIS DE ISOTIOURÔNIO, DE N- FENILISOTIOURÔNIO E DE ISOTIOSSEMICARBAZIDAS EM LINHAGENS DE MELANOMA

  2014cites this paper
• Biology of Human Tumors Activating FGFR 2 – RAS – BRAF Mutations in Ameloblastoma

  2014cites this paper
• Integrating molecular biomarkers into current clinical management in melanoma.

  2014cites this paper